Undecided direction on Korean distribution license for Gilead’s Sovaldi and Harvoni

Published: 2016-12-27 14:27:13

Updated: 2016-12-27 14:27:13

It is hard to predict where the Korean distribution license of ‘Sovaldi’ and ‘Harvoni,’ Gilead Sciences’ chronic hepatitis C treatments that have drawn interests of both pharmaceutical and distribution industries as large products, will go in the future.

According to the industry concerned, competition to acquire the Korean distribution license for Sovaldi and Harvoni is getting fiercer as it ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.